"Ranibizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.
| Descriptor ID |
D000069579
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.868 D12.776.124.790.651.114.224.060.868 D12.776.377.715.548.114.224.200.868
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ranibizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Ranibizumab [D12.776.124.486.485.114.224.060.868]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Ranibizumab [D12.776.124.790.651.114.224.060.868]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Ranibizumab [D12.776.377.715.548.114.224.200.868]
Below are MeSH descriptors whose meaning is more specific than "Ranibizumab".
This graph shows the total number of publications written about "Ranibizumab" by people in this website by year, and whether "Ranibizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 17 | 3 | 20 |
| 2018 | 11 | 2 | 13 |
| 2019 | 4 | 3 | 7 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ranibizumab" by people in Profiles.
-
OUTCOMES IN PATIENTS RESUMING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOLLOWING TREATMENT DELAY DURING THE CORONAVIRUS-19 PANDEMIC. Retina. 2021 12 01; 41(12):2456-2461.
-
The impact of delayed anti-vascular endothelial growth factor treatment for retinal diseases during the COVID-19 lockdown. Photodiagnosis Photodyn Ther. 2021 Sep; 35:102449.
-
Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity. Graefes Arch Clin Exp Ophthalmol. 2021 Jul; 259(7):1773-1780.
-
Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown. Indian J Ophthalmol. 2021 Mar; 69(3):730-733.
-
Intravitreal Anti-Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic. JAMA Ophthalmol. 2021 02 01; 139(2):240-242.
-
The Effect of Delay in Care among Patients Requiring Intravitreal Injections. Ophthalmol Retina. 2021 10; 5(10):975-980.
-
Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence. Eye (Lond). 2021 10; 35(10):2793-2801.
-
TriPla Regimen: A new treatment approach for patients with neovascular age-related macular degeneration in the COVID-19 "era". Eur J Ophthalmol. 2021 May; 31(3):849-852.
-
Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol. 2020 Dec; 258(12):2621-2628.
-
Retinal vein occlusion in COVID-19: A novel entity. Indian J Ophthalmol. 2020 Oct; 68(10):2291-2293.